ChemicalBook >> CAS DataBase List >>Fosphenytoin sodium

Fosphenytoin sodium

CAS No.
92134-98-0
Chemical Name:
Fosphenytoin sodium
Synonyms
CI 982;Cetebyx;ACC-9653;FOSPENYTOIN;ACC 9653-010;Pro-Epanutin;FOSPHENYTOIN SODIUM;Fosphenytion SodiuM;Fosphenytoin SodiuM USP;FOSPHENYTOIN DISODIUM SALT
CBNumber:
CB4692780
Molecular Formula:
C16H16N2NaO6P
Molecular Weight:
386.28
MDL Number:
MFCD00948765
MOL File:
92134-98-0.mol
Last updated:2024-11-19 23:02:33

Fosphenytoin sodium Properties

Melting point 220° (softens)
storage temp. Inert atmosphere,2-8°C
solubility H2O: ≥15mg/mL
form powder
color white to tan
FDA UNII 7VLR55452Z
NCI Drug Dictionary fosphenytoin sodium

Pharmacokinetic data

Protein binding 95-99%
Excreted unchanged in urine 1-5%
Volume of distribution 4.3-10.8 Litres
Biological half-life 18.9 (IV), 41.2 (IM) / Unchanged

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictogramsGHS hazard pictograms
GHS07,GHS08
Signal word  Danger
Hazard statements  H302-H350-H360
Precautionary statements  P201-P301+P312+P330-P308+P313
Hazard Codes  T
Risk Statements  45-61-22
Safety Statements  53-36/37-45
RIDADR  UN 2811 6.1 / PGIII
WGK Germany  3
HS Code  2933290000
Toxicity LD50 in mice, rats (mg/kg): 234, 363 i.v. (Smith)
NFPA 704
0
2 0

Fosphenytoin sodium price More Price(14)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich SML0117 Fosphenytoin disodium salt hydrate ≥98% (HPLC) 92134-98-0 5mg $163 2024-03-01 Buy
Sigma-Aldrich F-078 Fosphenytoindisodiumsaltsolution 1?mg/mLinmethanol((asphosphate)),certifiedreferencematerial,ampuleof1? 92134-98-0 1ML $108 2024-03-01 Buy
Sigma-Aldrich 1286366 Fosphenytoin sodium 92134-98-0 350mg $856 2024-03-01 Buy
Cayman Chemical 23889 Fosphenytoin (sodium salt) ≥98% 92134-98-0 50mg $44 2024-03-01 Buy
Cayman Chemical 23889 Fosphenytoin (sodium salt) ≥98% 92134-98-0 100mg $84 2024-03-01 Buy
Product number Packaging Price Buy
SML0117 5mg $163 Buy
F-078 1ML $108 Buy
1286366 350mg $856 Buy
23889 50mg $44 Buy
23889 100mg $84 Buy

Fosphenytoin sodium Chemical Properties,Uses,Production

Originator

Cerebyx,Pfizer

Uses

Anti epileptic

Uses

PDE3 (phosphodiesterase 3) inhibitor

Uses

Fosphenytoin sodium is used in the treatment of epileptic seizures.

Manufacturing Process

By action of formaldehyde and hydrochloric acid on 5,5-diphenylhydantoin was prepared 3-hydroxymethyl-5,5-diphenyl-imidazolidine-2,4-dione which was converted by action PCl3 to 3-chloromethyl-5,5-diphenyl-imidazolidine-2,4- dione by action PCl3. Then the chlorine atom was substituted on P(O)(OBz)Ogroup by action of argentum salt of phosphoric acid dibenzyl ester. Removal of the protecting groups by hydrogenolysis gives the 2,4-imidazolidinedione, 5,5- diphenyl-3-((phosphonooxy)methyl)- (fosphenytoin).
In practice it is usually used as sodium salt.

brand name

Cerebyx (Parke-Davis).

Therapeutic Function

Antiepileptic, Anticonvulsant

Clinical Use

Control of status epilepticus
Seizures associated with neurosurgery or head injury when oral phenytoin is not possible

Drug interactions

Potentially hazardous interactions with other drugs Aminophylline and theophylline: concentration of both drugs reduced with aminophylline and theophylline. Analgesics: enhanced effect with NSAIDs; metabolism of methadone accelerated; possibly increases pethidine toxicity. Anthelmintics: concentration of albendazole and praziquantel reduced; concentration of fosphenytoin possibly increased by levamisole. Anti-arrhythmics: increased concentration with amiodarone; concentration of disopyramide and possibly dronedarone reduced - avoid with dronedarone. Antibacterials: level increased by clarithromycin, chloramphenicol, isoniazid, metronidazole, sulphonamides and trimethoprim (+ antifolate effect); concentration increased or decreased by ciprofloxacin; concentration of bedaquiline, doxycycline and telithromycin reduced - avoid with telithromycin; concentration reduced by rifamycins.
Anticoagulants: increased metabolism of coumarins (reduced effect but also reports of enhancement); possibly reduced apixaban, dabigatran, edoxaban and rivaroxaban concentration - avoid with dabigatran.
Antidepressants: antagonise anticonvulsant effect; concentration increased by fluoxetine and fluvoxamine and possibly sertraline; concentration of mianserin, mirtazapine and paroxetine and possibly tricyclics reduced; concentration reduced by St John’s wort - avoid.
Antiepileptics: concentration of both drugs reduced with carbamazepine, concentration may also be increased by carbamazepine, eslicarbazepine, ethosuximide, oxcarbazepine, stripentol and topiramate; concentration of ethosuximide, active oxcarbazepine metabolite, retigabine, rufinamide (concentration of phenytoin possibly increased), topiramate and valproate possibly reduced; concentration of eslicarbazepine, ethosuximide, lamotrigine, perampanel, tiagabine and zonisamide reduced; concentration of phenobarbital often
increased; phenobarbital and valproate may alter concentration; concentration reduced by vigabatrin.
Antifungals: concentration of ketoconazole, itraconazole, posaconazole, voriconazole and possibly isavuconazole and caspofungin reduced - avoid with isavuconazole and itraconazole, increase voriconazole dose and possibly caspofungin; levels increased by fluconazole, miconazole and voriconazole - consider reducing fosphenytoin dose.
Antimalarials: avoid with piperaquine with artenimol, mefloquine and pyrimethamine - antagonise anticonvulsant effect; increased antifolate effect with pyrimethamine.
Antipsychotics: antagonise anticonvulsant effect; possibly reduced aripiprazole concentration - increase aripiprazole dose; metabolism of clozapine, haloperidol, quetiapine and sertindole increased; concentration increased or decreased with chlorpromazine; possibly reduces lurasidone concentration - avoid.
Antivirals: possibly reduced concentration of abacavir, boceprevir, daclatasvir, darunavir, dasabuvir, dolutegravir, indinavir, lopinavir, ombitasvir, paritaprevir, ritonavir, saquinavir and simeprevir - avoid with boceprevir, daclatasvir, dasabuvir, ombitasvir, paritaprevir and simeprevir; rilpivirine reduced - avoid; concentration possibly increased by indinavir and ritonavir; concentration increased or decreased with zidovudine; avoid with elvitegravir,
etravirine and telaprevir.
Apremilast: concentration of apremilast reduced - avoid.
Calcium-channel blockers: levels increased by diltiazem; concentration of diltiazem, felodipine, isradipine, nimodipine and verapamil reduced; avoid with isradipine and nimodipine.
Cannabis extract: concentration possibly reduced by phenytoin - avoid.
Ciclosporin: reduced ciclosporin levels.
Cobicistat: concentration of cobicistat possibly reduced.
Corticosteroids: metabolism accelerated (effect reduced)
. Cytotoxics: metabolism possibly inhibited by
fluorouracil; increased antifolate effect with methotrexate; reduced fosphenytoin absorption; concentration of busulfan, cabozantinib, ceritinib, eribulin, etoposide and imatinib reduced - avoid with cabozantib, ceritinib and imatinib; concentration possibly reduced by bosutinib, cisplatin ibrutinib and idelalisib - avoid with ibrutinib and idelalisib; possibly reduced concentration of axitinib, increase axitinib dose; possibly reduced concentration of crizotinib - avoid; avoid with cabazitaxel, gefitinib, lapatinib, olaparib, panobinostat, vemurafenib and vismodegib; concentration of irinotecan and its active metabolite reduced.
Dexrazoxane: absorption of fosphenytoin possibly reduced.
Disulfiram: metabolism of fosphenytoin inhibited. Diuretics: concentration increased by acetazolamide; concentration of eplerenone reduced - avoid; increased risk of osteomalacia with carbonic anhydrses inhibitors; antagonises effect of furosemide.
Guanfacine: concentration of guanfacine possibly reduced - increase dose of guanfacine.
Hormone antagonists: possibly reduced concentration of abiraterone - avoid; metabolism of toremifene accelerated.
Ivacaftor: concentration of ivacaftor possibly reduced - avoid.
Muscle relaxants: long-term use of phenytoin reduces effects of non-depolarising muscle relaxants, but acute use may enhance effects.
Oestrogens and progestogens: metabolism increased (reduced contraceptive effect).
Orlistat: possibly increased risk of convulsions.
Sulfinpyrazone: concentration increased by sulfinpyrazone.
Ulcer-healing drugs: metabolism inhibited by cimetidine; absorption reduced by sucralfate;
enhanced effect with esomeprazole and omeprazole.
Ulipristal: contraceptive effect possibly reduced - avoid.

Metabolism

Fosphenytoin is rapidly and completely hydrolysed to phenytoin with a conversion half-life of about 15 minutes; one mmol of fosphenytoin yields one mmol of phenytoin. Phenytoin is hydroxylated in the liver to inactive metabolites chiefly 5-(4-hydroxyphenyl)-5- phenylhydantoin by an enzyme system which is saturable. Phenytoin undergoes enterohepatic recycling and is excreted in the urine, mainly as its hydroxylated metabolite, in either free or conjugated form.

Fosphenytoin sodium Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 167)Suppliers
Supplier Tel Email Country ProdList Advantage
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512 info@tianfuchem.com China 21634 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32957 60
CONIER CHEM AND PHARMA LIMITED
+8618523575427 sales@conier.com China 49374 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000 marketing@targetmol.com United States 32165 58
Career Henan Chemica Co
+86-0371-86658258 +8613203830695 laboratory@coreychem.com China 30240 58
Xi'an MC Biotech, Co., Ltd.
029-89275612 +8618991951683 mcbio_sales@163.com China 2251 58
Baoji Guokang Healthchem co.,ltd
+8615604608665 15604608665 dominicguo@gk-bio.com CHINA 9414 58
Dayang Chem (Hangzhou) Co.,Ltd.
571-88938639 +8617705817739 info@dycnchem.com China 52849 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6391 58
Hefei TNJ Chemical Industry Co.,Ltd.
+86-0551-65418684 +8618949823763 sales@tnjchem.com China 25356 58

View Lastest Price from Fosphenytoin sodium manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Fosphenytoin disodium pictures 2024-11-19 Fosphenytoin disodium
92134-98-0
US $39.00-82.00 / mg 99.97% 10g TargetMol Chemicals Inc.
5,5-Diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt Fosphenytoin Sodium (350 mg) FOSPHENYTOIN SODIUM (sp-4-2)-5,5-diphenyl-3-((phosphonooxy)methyl)-2,4-imidazolidinedione disodium salt FOSPENYTOIN FOSPHENYTOIN DISODIUM SALT 5,5-Diphenyl-3-[[[di(sodiooxy)phosphinyl]oxy]methyl]-1H-imidazole-2,4(3H,5H)-dione ACC-9653 Fosphenytoin Sodium (250 mg) Fosphenytion SodiuM 5,5-Diphenyl-3-[(phosphonooxy)Methyl]-2,4-iMidazolidinedione SodiuM Salt ACC 9653-010 Cetebyx CI 982 Pro-Epanutin Fosphenytoin SodiuM USP 5,5-Diphenyl-3-[(phosphonooxy)methyl]-2,4-imidazolidinedione disodium salt hydrate Fosphenytoin disodium salt hydrate Fosphenytoin (sodium salt) disodium (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate Fosphenytoin Sodium (ACC-9653) Fosphenytoin Sodium (1286366) Phenytoin Impurity 11(Fosphenytoin Disodium Salt) isodium,(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methylphosphate Sodium (2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate 92134-98-0 C16H13N2O6P2Na C16H13N2Na2O6P C16H15N2O6P2Na C16H13N2O6P2NaH2O Heterocycles Intermediates & Fine Chemicals Pharmaceuticals API